Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Werewolf Therapeutics Inc
(NQ:
HOWL
)
6.750
+0.540 (+8.70%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
82,150
Open
6.220
Bid (Size)
6.000 (1)
Ask (Size)
7.050 (5)
Prev. Close
6.210
Today's Range
6.100 - 6.780
52wk Range
1.573 - 8.194
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
April 24, 2024
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting
April 23, 2024
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Performance
YTD
+45.47%
+45.47%
1 Month
+4.17%
+4.17%
3 Month
+37.76%
+37.76%
6 Month
+167.86%
+167.86%
1 Year
+184.81%
+184.81%
More News
Read More
Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting
April 05, 2024
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Recap: Werewolf Therapeutics Q4 Earnings
March 07, 2024
Via
Benzinga
Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting
April 04, 2024
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
HOWL Stock Earnings: Werewolf Therapeutics Beats EPS, Misses Revenue for Q4 2023
March 07, 2024
Via
InvestorPlace
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
March 07, 2024
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference
March 06, 2024
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024
March 05, 2024
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook
January 08, 2024
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors
January 04, 2024
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
January 04, 2024
Via
Benzinga
Werewolf Therapeutics to Present at the Evercore ISI HealthCONx Conference
November 22, 2023
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
November 14, 2023
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Top 5 Health Care Stocks That May Fall Off A Cliff This Month
November 06, 2023
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
November 03, 2023
Via
Benzinga
Why Fortinet Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Friday's Mid-Day Session
November 03, 2023
Via
Benzinga
Delta Air Lines Layoffs 2023: What to Know About the Latest DAL Job Cuts
November 03, 2023
Via
InvestorPlace
Topics
Workforce
Exposures
Layoff
CVNA Stock Alert: What Analysts Are Saying After Carvana’s Q3 Earnings
November 03, 2023
Via
InvestorPlace
Why Is Werewolf Therapeutics (HOWL) Stock Up 20% Today?
November 03, 2023
Via
InvestorPlace
Werewolf Therapeutics' Cancer Drug Shows Promise in Early Study for Solid Tumors, Stock Soars
November 03, 2023
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
November 03, 2023
Via
Benzinga
Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
November 03, 2023
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Why STAAR Surgical Shares Are Trading Lower By Around 16%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
November 02, 2023
Via
Benzinga
Why Roku Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket
November 02, 2023
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.